ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB

MLA

Magrey, M., et al. “Achievement of Increasingly Stringent Clinical Response Criteria and Lower Levels of Disease Activity Was Associated with Greater Improvements in Physical Function and Hrqol in Patients with Active Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies on Bimekizumab.” Annals of the Rheumatic Diseases, vol. 82, June 2023, p. 1721. EBSCOhost, https://doi.org/10.1136/annrheumdis-2023-eular.760.

APA

Magrey, M., Deodhar, A., Mease, P. J., Navarro-Compán, V., Ramiro, S., Rudwaleit, M., De la Loge, C., Fleurinck, C., Taieb, V., Morup, M., Oortgiesen, M., & Kay, J. (2023). Achievement of Increasingly Stringent Clinical Response Criteria and Lower Levels of Disease Activity Was Associated with Greater Improvements in Physical Function and Hrqol in Patients with Active Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies on Bimekizumab. Annals of the Rheumatic Diseases, 82, 1721. https://doi.org/10.1136/annrheumdis-2023-eular.760

Chicago

Magrey, M., A. Deodhar, P. J. Mease, V. Navarro-Compán, S. Ramiro, M. Rudwaleit, C. De la Loge, et al. 2023. “Achievement of Increasingly Stringent Clinical Response Criteria and Lower Levels of Disease Activity Was Associated with Greater Improvements in Physical Function and Hrqol in Patients with Active Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies on Bimekizumab.” Annals of the Rheumatic Diseases 82 (June): 1721. doi:10.1136/annrheumdis-2023-eular.760.